logo-loader

Starpharma Holdings' cabazitaxel is second DEP product to enter clinical stage

Published: 12:47 31 Jan 2018 AEDT

Picture of a laboratory
The alternative Jevtana sales are tipped to reach approximately US$500 million this year

Starpharma Holdings Limited’s (ASX:SPL) (OTCQX:SPHRY) approval to commence its phase I/II clinical trial for DEP® cabazitaxel is an important milestone.

The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP® cabazitaxel.

This is central to defining a recommended phase II dose (RP2D), and then to determining anti-tumour efficacy of the product in select tumour types.

Transitions DEP® product from portfolio to clinic

The approval advances DEP® cabazitaxel, Starpharma’s second DEP® product, from its internal portfolio to the clinic.

DEP® cabazitaxel has already delivered impressive pre-clinical results showing sustained efficacy and survival benefits.

it has also eliminated neutropenia, which is a significant dose-limiting side effect of many anti-cancer drugs, including Jevtana®.

Jevtana® sales expected to reach circa US$500 million

DEP® cabazitaxel is Starpharma’s detergent-free version of cancer drug, Jevtana®, which is marketed by global pharmaceutical group Sanofi Aventis.

It is used in the treatment of advanced prostate cancer.

The drug is also under clinical development for a range of other cancer types, including testicular, ovarian, breast, bladder, and head and neck.

Jevtana® sales are estimated to reach approximately US$500 million this year.

Follows success of DEP® docetaxel

DEP® cabazitaxel is the second product from Starpharma’s DEP® platform to enter the clinic.

It follows DEP® docetaxel, which delivered positive phase I clinical results in 2017 and recently progressed to phase II.

The reproducible benefits observed for DEP® docetaxel and DEP® cabazitaxel in pre-clinical models included decreased bone marrow toxicity and enhanced efficacy.

In both cases DEP® has also allowed for a detergent-free formulation resulting in significant additional benefits for patients. 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

9 hours, 14 minutes ago